AstraZeneca PLC reported that the FDA's advisory committee did not support camizestrant as a treatment for advanced breast cancer, with a 3 to 6 vote against its benefit-risk profile on May 1, 2026. Despite this setback, AstraZeneca remains confident in its potential based on earlier positive trial results, which showed a 56% reduction in disease progression risk compared to standard treatment.